Ipamorelin references have different jobs.
You’ll find these links throughout the pages. Each source helps with a particular question; none answers all of them.
Hormones and blood levels
The early work helps explain interest in Ipamorelin. The published human timing study helps explain two familiar numbers. Neither establishes a lasting everyday benefit.
Gobburu and colleagues’ human timing study (1999, Pharmaceutical Research) measured healthy men given infusions into a vein. It is the source of the roughly two-hour half-life estimate and the hormone peak at about forty minutes. It didn’t test sleep or recovery benefits, or an under-skin dosing interval.
Raun and colleagues’ early hormone experiments (1998, European Journal of Endocrinology) tested cells from rats as well as live rats and pigs. The pig hormone pattern helps explain the interest in this mechanism. It doesn’t show that long-term use is safe for people.
For the timing result in everyday terms, read the half-life page. The population and route are part of the finding.
Eating again after bowel surgery
The surgery research tested a practical benefit. Its results need a separate reading from the experiment that measured a hormone response.
Beck, Sweeney and McCarter’s published trial (2014, International Journal of Colorectal Disease) compared intravenous Ipamorelin with placebo after bowel surgery. Time to a first tolerated meal was the main measure. The difference wasn’t statistically significant, so the trial didn’t demonstrate that benefit.
The second surgery trial’s registry record, NCT01280344, describes a larger study completed in 2014. No results were posted there as of October 1, 2026. We therefore leave the outcome open; completion alone tells us nothing about whether the treatment helped.
Our research page puts these studies together without treating a hormone finding as a substitute for a clinical result.
Safety, compounding and care
These documents explain official concerns and the rules around care. They play a different part from a trial testing whether a treatment helped.
The bulk-substance safety page from FDA carries an April 22, 2026 content date. For Ipamorelin acetate, it shows Category 2 under 503B and a withdrawn 503A nomination. Withdrawal isn’t clearance. FDA’s 2024 Ipamorelin review explains preparation concerns, study events and missing safety data.
FDA’s explanation of compounding distinguishes those preparations from medicines with agency approval. Telemedicine policy (Federation of State Medical Boards, 2022) discusses assessment and the patient’s location. It’s a model for state boards, not one nationwide law.
The safety page separates observed events from concerns about possible risks. A source can explain a concern without settling it.